Skip to main content
. Author manuscript; available in PMC: 2018 Oct 23.
Published in final edited form as: Clin Exp Metastasis. 2017 Oct 23;34(6-7):401–410. doi: 10.1007/s10585-017-9864-8

Figure 1. EGFR amplification promotes metabolic reprogramming.

Figure 1

A) Amplification of EGFR activates mTORC2, AKT, and c-Myc to promote metabolic reprogramming. EGFR variant III is shown as a representative mutation causing EGFR activation because it is commonly found in glioblastoma and breast cancer (77, 78). B) AKT and c-Myc (in green) activate enzymes (in blue) involved in glycolysis, the pentose phosphate pathway, and glutamine catabolism to supply energy and macromolecules to rapidly proliferating cancer cells.

Reprinted by permission from Elsevier: Cell Press, copyright 2014.

Masui K, Cavenee WK, Mischel PS. (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends in endocrinology and metabolism: TEM. 25: 364–73. PMID: 24856037; PMCID: PMC4077930